Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $16.45, for a total value of $98,700.00. Following the transaction, the general counsel now owns 105,386 shares in the company, valued at $1,733,599.70. This trade represents a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA traded up $0.26 on Wednesday, reaching $16.77. The company’s stock had a trading volume of 627,614 shares, compared to its average volume of 518,437. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm’s 50 day moving average is $16.45 and its two-hundred day moving average is $16.36. The stock has a market cap of $2.21 billion, a PE ratio of -10.96 and a beta of 1.54.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CNTA shares. Morgan Stanley reissued an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $26.00.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $31,000. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC raised its position in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $171,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.